Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04319224 · ClinicalTrials.gov registry record · Phase 1
Vopratelimab (JTX-2011) Alone and in Combination With Anti-Programmed Cell Death Protein 1 (PD-1) or Anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) in Subjects With Advanced and/or Refractory Solid Tumors
A Phase 1 study, sponsored by Jounce Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT04319224: Clinical Trial Phase 1 study, sponsored by Jounce Therapeutics.
NCT04319224 is a Phase 1 study that was terminated before completion, run by Jounce Therapeutics. The registered enrollment target is 4 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04319224, a Phase 1 study, was terminated before completion, sponsored by Jounce Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
JTX-2011-R01 is an open label, multicenter, rollover study that is designed to provide continued access to vopratelimab for eligible subjects with advanced solid tumor malignancies who have previously participated in a vopratelimab study (the parent study).
Interventions
- DRUG Nivolumab
- DRUG Ipilimumab
- DRUG Vopratelimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2020-03-10 |
| Est. Completion | 2023-01-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04319224
The ClinicalTrials.gov registry entry for NCT04319224 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jounce Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Nivolumab is the first listed.
NCT04319224 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04319224 about?
NCT04319224 is a clinical study titled "Vopratelimab (JTX-2011) Alone and in Combination With Anti-Programmed Cell Death Protein 1 (PD-1) or Anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) in Subjects With Advanced and/or Refractory Solid Tumors". JTX-2011-R01 is an open label, multicenter, rollover study that is designed to provide continued access to vopratelimab for eligible subjects with advanced solid tumor malignancies who have previously participated in a vopratelimab study (the parent study).
What is the current status of trial NCT04319224?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2020-03-10. Estimated completion is 2023-01-03.
What interventions are being tested in trial NCT04319224?
The interventions under investigation include: Nivolumab (DRUG), Ipilimumab (DRUG), Vopratelimab (DRUG).
Who is sponsoring clinical trial NCT04319224?
This trial is sponsored by Jounce Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.